# G2E Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/g2e-co

- Industry: Medical Devices & Equipment
- Headquarters: Seoul, South Korea
- Website: www.g2e.co.kr
- Total disclosed funding: $17M
- Latest round: Series B (Dec 8, 2023)
- Investors on record: 9

## About

Based in Seoul, South Korea, and founded in 2000, G2E Co., Ltd. operates as a healthcare platform company that manufactures and sells platform-based insulin auto-injectors to help treat diabetes. In April 2023, G2E Co., Ltd. raised KRW 8.5 billion in Series B funding from investors SORISB and Huons Medicare, with participation from returning investors SEMA Translink Investment, Kolon Investment, and DAYLI Partners. As of April 2023, the company is being led by its CEO, Chung Chang-beom Jitui. 

The firm manufactures and sells platform-based insulin auto-injectors such as pumps and pens used in diabetes treatment and solutions. The firm also operates a patient care and diagnosis platform that enables users to examine patients remotely, utilize diagnostic equipment, and coordinate with doctors.

## Funding rounds

- Series B, Dec 8, 2023, $4.5M — DA Value Investment, Huons
- Series B, Apr 24, 2023, $6.4M — Kolon Investment, SEMA Translink Investment, DAYLI Partners, Huons, SORISB
- Series A, Dec 30, 2021, $5.5M — Kolon Investment, NH Investment & Securities, SEMA Translink Investment, DAYLI Partners, i-SENS
- Series A, Jul 16, 2020, $0.8M — Geon Investment

## Investors

- Geon Investment (https://capitalatlas.ai/funds/geon-investment) — Series A
- Kolon Investment (https://capitalatlas.ai/funds/kolon-investment) — Series A, Series B
- NH Investment & Securities (https://capitalatlas.ai/funds/nh-investment-securities) — Series A
- SEMA Translink Investment — Series A, Series B
- DAYLI Partners (https://capitalatlas.ai/funds/dayli-partners) — Series A, Series B
- i-SENS — Series A
- Huons — Series B
- SORISB — Series B
- DA Value Investment (https://capitalatlas.ai/funds/da-value-investment) — Series B